Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 16/20 | 0.80 |
| ▸ | NR1H2 | P55055 | 3/20 | 0.60 |
| ▸ | NR1H3 | Q13133 | 3/20 | 0.60 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.57 |
| ▸ | RORA | P35398 | 1/20 | 0.56 |
| ▸ | RORC | P51449 | 1/20 | 0.56 |
| ▸ | RORB | Q92753 | 1/20 | 0.56 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5564305 | 0.89 | HSD11B1 (1.00) | HSD11B1NR1H2NR1H3NR1I2RORA | |
| SCHEMBL14613566 | 0.87 | HSD11B1 (0.61) | HSD11B1NR1H2NR1H3NR1I2RORA | |
| SCHEMBL4599206 | 0.87 | HSD11B1 (0.65) | HSD11B1NR1H2NR1H3 | |
| SCHEMBL5565824 | 0.85 | HSD11B1 (1.00) | HSD11B1NR1H2NR1H3NR1I2 | |
| SCHEMBL14600038 | 0.84 | HSD11B1 (0.71) | HSD11B1 | |
| SCHEMBL4598847 | 0.84 | HSD11B1 (0.75) | HSD11B1NR1H2NR1H3 | |
| SCHEMBL12577226 | 0.84 | HSD11B1 (0.75) | HSD11B1NR1H2NR1H3 | |
| SCHEMBL18235558 | 0.84 | HSD11B1 (1.00) | HSD11B1NR1H2NR1H3NR1I2RORA | |
| SCHEMBL5564463 | 0.81 | HSD11B1 (1.00) | HSD11B1 | |
| SCHEMBL5567765 | 0.81 | HSD11B1 (1.00) | HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8076376-B2 | Aniline sulfonamide derivatives and their uses | AMGEN INC. | 2011-12-13 | — | — | US | claimed |
| EP-1907357-A1 | ANILINE SULFONAMIDE DERIVATIVES AND THEIR USES | Amgen Inc. (US) | 2008-04-09 | — | — | EP | claimed |
| WO-2007013929-A1 | ANILINE SULFONAMIDE DERIVATIVES AND THEIR USES | AMGEN INC. (US) | 2007-02-01 | — | — | WO | claimed |
| US-20070021502-A1 | Aniline sulfonamide derivatives and their uses | AMGEN INC. | 2007-01-25 | — | — | US | claimed |
| US-8076376-B2 | Aniline sulfonamide derivatives and their uses | AMGEN INC. | 2011-12-13 | — | — | US | disclosed |
| US-8076376-B2 | Aniline sulfonamide derivatives and their uses | AMGEN INC. | 2011-12-13 | — | — | US | disclosed |
| US-8076376-B2 | Aniline sulfonamide derivatives and their uses | AMGEN INC. | 2011-12-13 | — | — | US | disclosed |
| WO-2007013929-A1 | ANILINE SULFONAMIDE DERIVATIVES AND THEIR USES | AMGEN INC. (US) | 2007-02-01 | — | — | WO | disclosed |
| US-20070021502-A1 | Aniline sulfonamide derivatives and their uses | AMGEN INC. | 2007-01-25 | — | — | US | disclosed |
| US-20070021502-A1 | Aniline sulfonamide derivatives and their uses | AMGEN INC. | 2007-01-25 | — | — | US | disclosed |
| US-20070021502-A1 | Aniline sulfonamide derivatives and their uses | AMGEN INC. | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021502-A1 | Aniline sulfonamide derivatives and their uses | ARSA, SULT2A1, SULT1A1 | HSD11B1 680/4885NR1H2 416/4885NR1H3 414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.